Positive results from second pivotal Phase 3 study of Brodalumab in patients with moderate-to-severe plaque psoriasis announced

Amgen and AstraZeneca has announced that AMAGINE-3(TM), a pivotal, multi-arm Phase 3 trial evaluating two doses of brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis...